CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.